Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest Expenses (2016 - 2025)

China Pharma Holdings' Interest Expenses history spans 16 years, with the latest figure at $6879.0 for Q4 2025.

  • For Q4 2025, Interest Expenses rose 1.13% year-over-year to $6879.0; the TTM value through Dec 2025 reached $27243.0, changed 0.4%, while the annual FY2025 figure was $27272.0, 0.3% changed from the prior year.
  • Interest Expenses reached $6879.0 in Q4 2025 per CPHI's latest filing, up from $6798.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $245056.0 in Q4 2021 to a low of -$252776.0 in Q4 2023.
  • Average Interest Expenses over 5 years is $11515.4, with a median of $6847.5 recorded in 2024.
  • The largest YoY upside for Interest Expenses was 2969.86% in 2022 against a maximum downside of 199.81% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $245056.0 in 2021, then crashed by 199.81% to -$244593.0 in 2022, then fell by 3.35% to -$252776.0 in 2023, then skyrocketed by 102.69% to $6802.0 in 2024, then increased by 1.13% to $6879.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Interest Expenses are $6879.0 (Q4 2025), $6798.0 (Q3 2025), and $6779.0 (Q2 2025).